COST SAVINGS IN TYPE-2 DIABETES (T2D) WITH INSULIN GLARGINE COMPARED WITH INSULIN DETEMIR IN THE UNITED KINGDOM

被引：0
|
作者：
Tilling, C. [1 ]
Evans, L. M. [2 ]
Keech, M. [3 ]
机构：
[1] Sanofi Aventis, Guildford, Surrey, England
[2] Univ Hosp Llandough, Penarth, S Glam, Wales
[3] Pharmakos, St Albans, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.536
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A96 / A96
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness of Insulin Icodec for the Treatment of Type 2 Diabetes (T2D) in Canada
    Garcia, David A.
    Mau, Godfrey
    Vuong, Vivian
    Singh, Sumeet
    Jensen, Morten S.
    Goldenberg, Ronald
    [J]. DIABETES, 2024, 73
  • [22] Comparison of the Effects of Insulin Detemir (IDet) and Insulin Glargine (IGlar) in Patients With Type 2 Diabetes (T2DM) in Turkey
    Damci, Taner
    Emral, Rifat
    Svendsen, Anne Louise
    Balkir, Tanzer
    Vora, Jiten
    [J]. DIABETES, 2013, 62 : A653 - A653
  • [23] Duration of Diabetes and Hypoglycemia Rates in T2D Patients Treated with Insulin Glargine vs NPH Insulin
    Dailey, George
    Aurand, Lisa A.
    Garg, Satish K.
    [J]. DIABETES, 2011, 60 : A602 - A602
  • [24] COST-MINIMIZATION ANALYSIS COMPARING INSULIN GLARGINE TO INSULIN DETEMIR IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS IN BRAZIL
    Bahia, L.
    Teich, V
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A506 - A506
  • [25] Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective
    Permsuwan, Unchalee
    Thavorn, Kednapa
    Dilokthornsakul, Piyameth
    Saokaew, Surasak
    Chaiyakunapruk, Nathorn
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (09) : 991 - 999
  • [26] COST COMPARISON OF INSULIN GLARGINE AND INSULIN DETEMIR IN TYPE 2 DIABETES MELLITUS IN ARGENTINA: ATRIAL-BASED PROBABILISTIC MODEL
    Pichon-Riviere, A.
    Caporale, J. E.
    Augustovski, F. A.
    von Schulz-Hausmann, C.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A506 - A506
  • [27] Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
    Asias, Bernadette D.
    Stock, Eileen M.
    Small, Nancy L.
    Getchell, Katerine E.
    Patel, Jagruti R.
    Krause, Jennifer D.
    Cavness, Staci
    Dzenowski, Cassidy L.
    Ta, Mia
    [J]. JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2015, 14
  • [28] Insulin detemir and insulin glargine: Similar time-action profiles in subjects with type 2 diabetes
    Klein, Oliver
    Lynge, Jan
    Endahl, Lars
    Damholt, Birgitte
    Nosek, Leszek
    Heise, Tim
    [J]. DIABETES, 2006, 55 : A76 - A76
  • [29] Insulin detemir and insulin glargine: similar time-action profiles in subjects with type 2 diabetes
    Heise, T.
    Klein, O.
    Lynge, J.
    Endahl, L.
    Damholt, B.
    Nosek, L.
    [J]. DIABETOLOGIA, 2006, 49 : 93 - 94
  • [30] Evaluation of the cost-utility of insulin detemir compared to insulin glargine, both in combination with insulin aspart in type-1 diabetes in Germany and Austria
    Roze, S
    Wittrup-Jensen, KU
    Valentine, WJ
    Palmer, AJ
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A166 - A167
12345